Can Abbvie keep winning forever? | Abbvie Stock Analysis
3.8 هزار بار بازدید -
3 سال پیش
-
Today we are looking at
Today we are looking at the big pharma giant, Abbvie. We look at what has helped them crush the competition for so long as well as what drugs are in their pipeline to keep them far ahead of everyone else.
Join Me on CommonStock: https://share.commonstock.com/share?i...
Follow Me on Twitter: Twitter: USD_with_Sense
Join My Discord: Discord: discord
Abbvie was started when Abbot Labs made the decision to spin the drug-producing segment of its business into its own company. Since then Abbvie has dominated the competition headed by blockbuster drug Humira.
Humira accounts for a whopping $20 billion dollars of revenue and is the best-selling prescription drug in the world right now. But there is a big problem. Humira's patent expires in 2023. This has left Abbvie scrambling to replace that massive revenue gap.
So of course this leads us to their pipeline and what drugs they got coming up. The two mains drugs are Rinvoq and Skyrizi, two drugs that Abbvie projects to make a combined 15 billion dollars of revenue by 2025. While not a complete replacement it's still a solid chunk. Another drug coming up is Vraylar, which, if approved will be used in the treatment of Autism Spectrum Disorder. And finally, the last pair I want to mention is AL002 and AL003 which are drugs that are in Phase 1 Trials in the treatment of Alzheimer's.
Speaking of Alzheimer's, you can support the cause here:
Alzheimer's Association Website: https://www.alz.org/
Parkinsons Foundation Website: https://www.parkinson.org/
Join Me on CommonStock: https://share.commonstock.com/share?i...
Follow Me on Twitter: Twitter: USD_with_Sense
Join My Discord: Discord: discord
Abbvie was started when Abbot Labs made the decision to spin the drug-producing segment of its business into its own company. Since then Abbvie has dominated the competition headed by blockbuster drug Humira.
Humira accounts for a whopping $20 billion dollars of revenue and is the best-selling prescription drug in the world right now. But there is a big problem. Humira's patent expires in 2023. This has left Abbvie scrambling to replace that massive revenue gap.
So of course this leads us to their pipeline and what drugs they got coming up. The two mains drugs are Rinvoq and Skyrizi, two drugs that Abbvie projects to make a combined 15 billion dollars of revenue by 2025. While not a complete replacement it's still a solid chunk. Another drug coming up is Vraylar, which, if approved will be used in the treatment of Autism Spectrum Disorder. And finally, the last pair I want to mention is AL002 and AL003 which are drugs that are in Phase 1 Trials in the treatment of Alzheimer's.
Speaking of Alzheimer's, you can support the cause here:
Alzheimer's Association Website: https://www.alz.org/
Parkinsons Foundation Website: https://www.parkinson.org/
3 سال پیش
در تاریخ 1400/06/24 منتشر شده
است.
3,871
بـار بازدید شده